| Expression pattern: |
UP |
| Associated gene: |
MYSM1, IER2 |
| Associated microRNA: |
miR-30a |
| Biological function: |
Enhances proliferation, accelerates cell cycle progression, and inhibits apoptosis in AML cells; associated with relapse. |
| Molecular mechanism: |
Acts as a competing endogenous RNA (miRNA sponge) for miR-30a, increasing expression of miR-30a targets (e.g., MYSM1 and IER2). |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); cell cycle (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA-seq; Clinical Sample Validation; Transfection; CCK8; Cell Cycle Assay; Annexin V/PI Flow Cytometry; TUNEL; RNA Pull-Down; Luciferase Reporter Assay; Bioinformatics Analysis; ROC Analysis; Survival Analysis; Cohort Study |
| Clinical significance: |
High circRNF220 distinguishes AML from controls/other hematological diseases with high sensitivity and specificity and independently predicts relapse (unfavorable prognostic marker). |
| Description: |
circRNF220 is up-regulated in pediatric AML (BM and PB) and serves as a diagnostic marker and an independent predictor of relapse (high expression indicates poorer relapse-free survival). Functionally, circRNF220 promotes AML cell proliferation/cell-cycle progression and suppresses apoptosis, at least partly by sponging miR-30a to increase expression of targets such as MYSM1 and IER2. |
| Confidence score: |
0.889 |